For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Choroidal neovascularization describes the growth of new blood vessels that originate from the choroid through a break in the Bruch membrane into the sub-retinal pigment epithelium (sub-RPE) or subretinal space.
LPI (LP Information)' newest research report, the "Choroidal Neovascularization Industry Forecast" looks at past sales and reviews total world Choroidal Neovascularization sales in 2022, providing a comprehensive analysis by region and market sector of projected Choroidal Neovascularization sales for 2023 through 2029. With Choroidal Neovascularization sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Choroidal Neovascularization industry.
This Insight Report provides a comprehensive analysis of the global Choroidal Neovascularization landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Choroidal Neovascularization portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Choroidal Neovascularization market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Choroidal Neovascularization and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Choroidal Neovascularization.
The global Choroidal Neovascularization market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Choroidal Neovascularization is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Choroidal Neovascularization is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Choroidal Neovascularization is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Choroidal Neovascularization players cover Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bayer AG, QLT Inc., Sanwa Kagaku Kenkyusho Co. Ltd., Promedior Inc. and Bausch Health, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Choroidal Neovascularization market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Intravenous
- Intravitreal
Segmentation by application
- Extreme Myopia
- Malignant Myopic Degeneration
- Age-Related Developments
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Bayer AG
- QLT Inc.
- Sanwa Kagaku Kenkyusho Co. Ltd.
- Promedior Inc.
- Bausch Health
- Gilead Sciences Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Choroidal Neovascularization market?
What factors are driving Choroidal Neovascularization market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Choroidal Neovascularization market opportunities vary by end market size?
How does Choroidal Neovascularization break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?